The index complements the existing search functionality by providing links to entries in the main body of the BNF text and to information in Appendices 6, 7 and 8 (Intravenous Additives, Borderline Substances, and Wound management products, respectively). Details in Appendix 1 (Interactions) and Appendices 2–5 (dealing with the use of medicines in liver disease, renal impairment, pregnancy and breast-feeding) are not indexed. These sections of the publication not covered by the index are easily accessed by browsing the main hierarchy or by using the full text search. In this respect the new index will also be useful for confirming the correct spelling of a term that can then be typed into the main search field.
Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics.  It has effects similar to the phenothiazines .  The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 = mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis.  Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .